generic speaker image
Paola Marignani PhD, MBA - Dalhousie University, Faculty of Medicine. Halifax, Canada Area, NS, CA

Paola Marignani PhD, MBA Paola Marignani PhD, MBA

Professor | Dalhousie University, Faculty of Medicine

Halifax, Canada Area, NS, CANADA

Dr. Paola Marignani is a scientist dedicated to developing personalized precision medicine that will improve human health.

Social

Areas of Expertise (13)

Breast Cancer Research

Lung cancer Research

Gene Editing

CRISPR-Cas9

Transgenic mouse models of cancer

Cancer Metabolism

Epigenetics

Signal Trasnduction

Signalling networks

Neurodegenerative Disorders Related to Ageing

Alzheimer's Disease Spectrum

tumor suppressors and oncogenes

DNA stability and damage

Education (7)

Ivey School of Business: MBA, Executive MBA 2013

Ontario Cancer Institute: PDF, Cancer 2002

Samuel Lunenfeld Research Institute- Mount Sinai Hospital: PDF, Mass Spectrometry 2001

Harvard Division of Signal Transduction: PDF, Fellow 2000

McMaster University: PhD, Cell Biology 1997

Western University (UWO): MSc Neuropathology 1992

University of Windsor: Honours BSC, Biology and Chemistry 1988

Languages (4)

  • English
  • Italian
  • French
  • Swedish

Media Appearances (6)

House hold chemicals

Global News  tv

Dr. Marignani and colleagues report on how low-dose exposure to common chemicals may contribute to the development of cancers and other diseases.

view more

Low dose chronic exposure to chemical mixtures

CTV  tv

Dr. Marignani, a member of the Halifax Project reports on how low-dose chronic exposure to common chemicals may contribute to the development of diseases.

view more

New Drug combination halts HER2+ breast cancer in mice engineered to develop cancer

Radio Canada  radio

Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.

Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.

view more

New Breast Cancer Treatment

Global News  tv

Dr. Paola Marignani and her team of scientists have discovered a new drug combination that halts HER2+ breast cancer from developing in mice re-engineered to develop breast cancer. The new drugs; AZD8055 and 2-DG when administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.

Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.

view more

Promising new drugs in the battle against breast cancer

CTV  tv

Promising new drugs have been discovered to be effective at halting HER2+ breast cancer in mice re-engineered to develop breast cancer. Dr. Paola Marignani and her team of scientists pre-clinically tested new drugs; AZD8055 and 2-DG. When administered alone, significantly inhibited tumour growth, however when combined, tumour growth was halted and pro-survival pathways that contribute to recurrence, were blocked.

Dr. Marignani is the first to combine treatments that attack two different molecular mechanisms; mTOR and glycolyisis.

view more

Novel drugs in the battle against breast cancer

Shedon McLeod Radio Show  radio

An interview with Dr. Paola Marignani who discovered a new drug combination that stops HER2+ breast cancer from developing in mice re-engineered to develop breast cancer.

view more